<span item_type="fundamental" item_id="a296badfd9b3b76960c5a335079e1efc" counter_id="ST/US/DMAAR" env="prod"></span><span item_type="announcement" item_id="549447141849698305" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD 0.12.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not commenced any operations and does not expect to generate operating revenues until after the completion of its initial Business Combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025076681/ea0252999-10q_drugs.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>For the three months ended June 30, 2025, the company reported a net income of $2,288,579, primarily due to interest earned on cash and investments held in the Trust Account amounting to $2,420,498, offset by general and administrative costs of $131,919.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025076681/ea0252999-10q_drugs.htm"></span></li><li>For the six months ended June 30, 2025, the company reported a net income of $3,543,122, with interest earned on cash and investments held in the Trust Account totaling $4,005,966, offset by general and administrative costs of $462,844.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025076681/ea0252999-10q_drugs.htm"></span></li><li>For the period from May 23, 2024 (inception) through June 30, 2024, the company reported a net loss of $54,931, consisting solely of general and administrative costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025076681/ea0252999-10q_drugs.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the six months ended June 30, 2025 was - $357,899.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025076681/ea0252999-10q_drugs.htm"></span></li><li>Net cash used in investing activities for the same period was - $231,150,000, primarily due to investment of cash into the Trust Account.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025076681/ea0252999-10q_drugs.htm"></span></li><li>Net cash provided by financing activities was $231,507,370, mainly from proceeds from the sale of Units and Private Placement Units.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025076681/ea0252999-10q_drugs.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company has placed $231,150,000 in a Trust Account from the net proceeds of the Initial Public Offering and Private Placement Units.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025076681/ea0252999-10q_drugs.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li>The company intends to focus on companies in the pharmaceutical industry for its Business Combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025076681/ea0252999-10q_drugs.htm"></span></li><li>The company has until April 29, 2026, to complete a Business Combination, with the possibility of extending the period up to 21 months from the closing of the Initial Public Offering.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025076681/ea0252999-10q_drugs.htm"></span></li><li>The company plans to use the funds from the Trust Account to complete its initial Business Combination and finance the operations of the target business.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025076681/ea0252999-10q_drugs.htm"></span></li></ul>

DRUGS MADE IN AMER ACQUISITION CORP COM USD0.0001 15/10/2029 (SUB/RIGHTS) | 10-Q: FY2025 Q2 EPS: USD 0.12